A blood test using quantum sensing and AI to detect prostate cancer early
Tests a blood-based method for finding prostate cancer in adults.
Plain-language title generated from the registry record
Registry title: Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer
Key facts
- Where
- Beijing, Chengdu, Guangzhou, Nanjing, Ningbo, Shanghai, and Suzhou, ChinaSee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07238959, who can take part
Where in China
- Cancer Hospital, Chinese Academy of Medical SciencesBeijing, ChinaNo longer taking part
- West China Hospital，Sichuan UniversityChengdu, ChinaNo longer taking part
- The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaNo longer taking part
- Jiangsu Provincial People's HospitalNanjing, ChinaNo longer taking part
- Ningbo No. 1 HospitalNingbo, ChinaNo longer taking part
- Shanghai Changzheng HospitalShanghai, ChinaNo longer taking part
- The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Changzheng Hospital
- Trial code
- NCT07238959
- Record updated
- 20 November 2025
- Original description
This research project aims to develop a novel blood testing method integrating cutting-edge quantum sensing and artificial intelligence technologies to achieve precise, non-invasive early diagnosis of prostate cancer. The research will employ quantum sensors to perform ultra-high-sensitivity measurements of circulating free DNA (cfDNA) in blood, thereby training a dedicated AI diagnostic model. The ultimate objective is to establish the diagnostic efficacy of this approach through clinical validation, providing clinicians with a novel diagnostic tool capable of significantly reducing unnecessary prostate biopsy procedures.Read full original descriptionShow less
Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer
This research project aims to develop a novel blood testing method integrating cutting-edge quantum sensing and artificial intelligence technologies to achieve precise, non-invasive early diagnosis of prostate cancer. The research will employ quantum sensors to perform ultra-high-sensitivity measurements of circulating free DNA (cfDNA) in blood, thereby training a dedicated AI diagnostic model. The ultimate objective is to establish the diagnostic efficacy of this approach through clinical validation, providing clinicians with a novel diagnostic tool capable of significantly reducing unnecessary prostate biopsy procedures.
Inclusion: Male, aged 18-80 years; PSA > 4 ng/ml; Patients meeting criteria for prostate biopsy:; fPSA/PSA < 0.16 or PSA D > 0.15 or PSA V > 0.75; ② Positive digital rectal examination (DRE); ③ Imaging studies (ultrasound/MRI) showing suspicious lesions.
Exclusion: Patients who have undergone transurethral resection or enucleation of the prostate; Patients who have previously received treatment for prostate cancer, including but not limited to endocrine therapy, targeted therapy, or immunotherapy; Patients on long-term anticoagulant or antiplatelet therapy (anticoagulants discontinued for less than one week); Patients who have received any form of tumour treatment prior to enrolment blood sampling, including surgery, radiotherapy/chemotherapy, endocrine therapy, targeted therapy, or immunotherapy; Concurrent severe systemic diseases deemed by the investigator likely to interfere with trial treatment, evaluation, or compliance, including serious respiratory, circulatory, neurological, psychiatric, gastrointestinal, endocrine, immunological, or urological disorders; Organ transplant recipients or individuals with prior non-autologous (allogeneic) bone marrow or stem cell transplantation; Subjects who have undergone blood transfusion within one month prior to blood sampling; Patients diagnosed with any malignant tumour within the past five years; Patients currently participating in other clinical trials, or who have participated in other clinical trials within the past year; Patients deemed unsuitable for this clinical trial by the investigator; Patients meeting any of the above criteria shall not be eligible for inclusion as subjects.